The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment‐naive patients with type 2 diabetes mellitus
Abstract
Aim: To compare the efficacy and safety of vildagliptin and metformin initial combination therapy with individual monotherapies in treatment‐naive patients with type 2 diabetes mellitus (T2DM). Methods: This was a 24‐week, randomized, double‐blind, active‐controlled study. Treatment‐naive patients with T2DM who had a glycated haemoglobin (HbA 1c ) of 7.5–11% (N = 1179) were randomized equally to receive vildagliptin plus high‐dose metformin combination therapy (50 mg + 1000 mg twice daily), vildagliptin plus low‐dose metformin combination therapy (50 mg + 500 mg twice daily), vildagliptin monotherapy (50 mg twice daily) or high‐dose metformin monotherapy (1000 mg twice daily). The primary objective was to demonstrate that HbA 1c reduction from baseline with either combination therapy is superior to both monotherapies at the week 24 endpoint. Patients who failed glycaemic‐screening criteria [HbA 1c >11% or fasting plasma glucose (FPG) >15 mmol/l (270 mg/dl)] could enter a 24‐week, single‐arm substudy. These patients (N = 94) received open‐label vildagliptin plus high‐dose metformin combination therapy (100 mg + 1000 mg twice daily). Results: From comparable baseline values (8.6–8.7%), HbA 1c decreased in all four treatment groups, to the greatest extent with vildagliptin plus high‐dose metformin combination therapy. Mean (SE) HbA 1c change from baseline was −1.8% (0.06%), −1.6% (0.06%), −1.1% (0.06%) and −1.4% (0.06%) with vildagliptin plus high‐dose metformin combination therapy, vildagliptin plus low‐dose metformin combination therapy, and vildagliptin and metformin monotherapies respectively. The between‐group difference was superior with vildagliptin plus high‐dose metformin combination therapy (p < 0.001 vs. both monotherapies) and vildagliptin plus low‐dose metformin combination therapy (p < 0.001 and p = 0.004, vs. vildagliptin and metformin monotherapies, respectively). Higher baseline HbA 1c values were linked to greater HbA 1c reductions, with changes of −3.2% (0.22%), −2.7% (0.22%), −1.5% (0.24%) and −2.6% (0.26%) respectively, occurring in patients with baseline HbA 1c ≥10%. Reductions in FPG were superior with vildagliptin plus high‐dose metformin combination therapy [change from baseline −2.63 (0.13) mmol/l] compared with both monotherapies [−1.26 (0.13) mmol/l and −1.92 (0.13) mmol/l, respectively; p < 0.001]. There was no incidence of hypoglycaemia or severe hypoglycaemia with either combination therapy, and neither was associated with weight gain. All treatments were well tolerated and displayed a comparable incidence of adverse events overall. Despite superior HbA 1c lowering, the vildagliptin plus low‐dose metformin combination therapy group demonstrated a favourable gastrointestinal (GI) tolerability profile compared with metformin monotherapy. Conclusions: In treatment‐naive patients, combinations of vildagliptin and both high‐dose and low‐dose metformin provide superior efficacy to monotherapy treatments with a comparable overall tolerability profile and low risk of hypoglycaemia. The potential dose‐sparing effect of adding vildagliptin to low‐dose metformin in preference to the up‐titration of metformin may allow patients to achieve equivalent or superior HbA 1c lowering without the GI tolerability issues associated with higher doses of metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Finding New Treatments for Diabetes — How Many, How Fast . . . How Good?
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068294 · Cited by 216
Rosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Cited by
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Metadata
- Authors
- Bosi, E., Dotta, F., Jia, Y., & Goodman, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-04-15
- Volume
- 11
- Issue
- 5
- Pages
- 506-515
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2137471483
- Cited by
- 173
- References
- 6
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment‐naive patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01040.x
- The paper
- Bosi, E., Dotta, F., Jia, Y., & Goodman, M. (2009). Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment‐naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01040.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.